Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968669 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT00968669: Completed Phase 2 study, sponsored by MedImmune.
NCT00968669 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 329 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968669, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
Primary Outcome
Change at Day 92 from baseline (Day 1, prior to dosing) in mean ACQ scores in pariticpants receiving 30, 100, or 300 mg MEDI-528 versus placebo (Intent-to-Treat Analysis). The 6-item ACQ is a participant-reported questionnaire assessing asthma symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use. Participants were asked to recall how their asthma had been during the previous week. Questions were weighted equally
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI528 30 mg
- BIOLOGICAL MEDI528 100 mg
- BIOLOGICAL MEDI528 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00968669 record still lists
NCT00968669 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00968669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00968669 about?
NCT00968669 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults". To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
What is the current status of trial NCT00968669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2009-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00968669?
The interventions under investigation include: Placebo (OTHER), MEDI528 30 mg (BIOLOGICAL), MEDI528 100 mg (BIOLOGICAL), MEDI528 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00968669?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00968669's enrollment target sits among peer trials
329 146th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia